Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503224
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-07
Brief Title:
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SCAR02
Brief Summary:
This is an open label single-site dose-escalation study in up to 18 participants with refractory autoimmune diseases This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None